Catalyst Pharmaceutical
CPRX
CPRX was delisted on the 14th of July, 2026.
47 hedge funds and large institutions have $56.4M invested in Catalyst Pharmaceutical in 2014 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 14 increasing their positions, 3 reducing their positions, and 6 closing their positions.
367% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 3
335% more call options, than puts
Call options by funds: $87K | Put options by funds: $20K
150% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 6
138% more capital invested
Capital invested by funds: $23.7M → $56.4M (+$32.8M)
24% more funds holding
Funds holding: 38 → 47 (+9)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
+$5.53M |
| 2 |
BC
Broadfin Capital
New York
|
+$5.13M |
| 3 |
BBA
Baker Bros. Advisors
New York
|
+$3.53M |
| 4 |
PA
Perceptive Advisors
New York
|
+$3.2M |
| 5 |
VAM
Visium Asset Management
New York
|
+$3.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$175K |
| 2 |
U
UBS
Zurich,
Switzerland
|
-$69.5K |
| 3 |
CAN
Cetera Advisor Networks
El Segundo,
California
|
-$54K |
| 4 |
QIM
Quantitative Investment Management
Charlottesville,
Virginia
|
-$25K |
| 5 |
Morgan Stanley
New York
|
-$7K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
51
Morgan Stanley
New York
| – | -$7K | -3,161 | Closed |
|
|
TRCT
52
Tower Research Capital (TRC)
New York
| – | -$1K | -534 | Closed |
|
53
AllianceBernstein
Nashville,
Tennessee
| – | -$1K | -364 | Closed |
|
CPRX Hedge Fund Activity: Q2 2014 in Review
47 of the 3,479 institutional investors tracked by Wall St. Rank reported a position in Catalyst Pharmaceutical (CPRX) for Q2 2014, worth a combined $56.4M — up 138% from $23.7M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new CPRX positions and 6 closed out — a net gain of 9 holders — while 14 added to existing stakes and 3 trimmed.
The largest buyer was Franklin Resources, opening a new position worth an estimated $5.53M. The largest seller was Federated Hermes, cutting an estimated $175K.
- 47 institutional investors held Catalyst Pharmaceutical (CPRX) as of Q2 2014, up from 38 in Q1 2014.
- Funds reported $56.4M of Catalyst Pharmaceutical stock for Q2 2014, up 138% quarter-over-quarter.
- 15 funds opened new Catalyst Pharmaceutical positions in Q2 2014 and 6 closed out, a net change of +9 holders.
- The largest Catalyst Pharmaceutical buyer in Q2 2014 was Franklin Resources, an estimated $5.53M added.
- The largest Catalyst Pharmaceutical seller in Q2 2014 was Federated Hermes, an estimated $175K sold.
Based on aggregated 13F filings for Q2 2014.